JP2018510636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510636A5 JP2018510636A5 JP2017549507A JP2017549507A JP2018510636A5 JP 2018510636 A5 JP2018510636 A5 JP 2018510636A5 JP 2017549507 A JP2017549507 A JP 2017549507A JP 2017549507 A JP2017549507 A JP 2017549507A JP 2018510636 A5 JP2018510636 A5 JP 2018510636A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- cdr3
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 100
- 108091007433 antigens Proteins 0.000 claims description 100
- 239000012634 fragment Substances 0.000 claims description 56
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 30
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 16
- 102000046810 human CEACAM6 Human genes 0.000 claims description 14
- 241000282567 Macaca fascicularis Species 0.000 claims description 10
- 229940125644 antibody drug Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108010062802 CD66 antigens Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 2
- 102220470708 Carcinoembryonic antigen-related cell adhesion molecule 6_I63F_mutation Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 102000055639 human CEACAM3 Human genes 0.000 claims description 2
- 102000047627 human CEACAM5 Human genes 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102220193249 rs1057516144 Human genes 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160292 | 2015-03-23 | ||
| EP15160292.7 | 2015-03-23 | ||
| PCT/EP2016/056104 WO2016150899A2 (en) | 2015-03-23 | 2016-03-21 | Anti-ceacam6 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212437A Division JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510636A JP2018510636A (ja) | 2018-04-19 |
| JP2018510636A5 true JP2018510636A5 (enExample) | 2019-02-21 |
| JP6815329B2 JP6815329B2 (ja) | 2021-01-20 |
Family
ID=52692556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549507A Active JP6815329B2 (ja) | 2015-03-23 | 2016-03-21 | 抗ｃｅａｃａｍ６抗体およびその使用 |
| JP2020212437A Active JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212437A Active JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10584167B2 (enExample) |
| EP (2) | EP3274370B1 (enExample) |
| JP (2) | JP6815329B2 (enExample) |
| KR (1) | KR102749339B1 (enExample) |
| CN (1) | CN107743495B (enExample) |
| AR (1) | AR104047A1 (enExample) |
| AU (1) | AU2016236270B2 (enExample) |
| BR (1) | BR112017020373A2 (enExample) |
| CA (1) | CA2980390A1 (enExample) |
| CY (1) | CY1122627T1 (enExample) |
| DK (1) | DK3274370T3 (enExample) |
| ES (1) | ES2768784T3 (enExample) |
| HR (1) | HRP20192280T1 (enExample) |
| HU (1) | HUE048111T2 (enExample) |
| IL (1) | IL254534B (enExample) |
| LT (1) | LT3274370T (enExample) |
| MX (1) | MX376973B (enExample) |
| PE (1) | PE20171790A1 (enExample) |
| PL (1) | PL3274370T3 (enExample) |
| PT (1) | PT3274370T (enExample) |
| RS (1) | RS59878B1 (enExample) |
| RU (1) | RU2739163C2 (enExample) |
| SG (1) | SG11201707800QA (enExample) |
| SI (1) | SI3274370T1 (enExample) |
| TW (1) | TWI719969B (enExample) |
| WO (1) | WO2016150899A2 (enExample) |
| ZA (1) | ZA201707138B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2980390A1 (en) | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| WO2018070936A1 (en) | 2016-10-10 | 2018-04-19 | Singhealth Services Pte Ltd | Anti-ceacam6 antibodies and methods of use |
| US11220543B2 (en) * | 2016-11-14 | 2022-01-11 | Dinona | Antibody binding specifically to CD66c and use thereof |
| KR102014400B1 (ko) * | 2017-01-05 | 2019-08-28 | 한국생명공학연구원 | Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체 |
| EP3585819A4 (en) | 2017-02-27 | 2020-10-14 | Caerus Therapeutics, Inc. | ANTIBODY CONSTRUCTIONS AND CANCER TREATMENT METHODS |
| BR112019021182A2 (pt) | 2017-04-24 | 2020-06-02 | Memorial Sloan Kettering Cancer Center | Agentes de anticorpo anti-cd33 |
| CN111065653A (zh) * | 2017-05-23 | 2020-04-24 | 中央研究院 | 藉由预靶向的双特异性聚乙二醇结合抗体将聚乙二醇化试剂条件性内吞用于诊断和治疗 |
| ES2911243T3 (es) * | 2017-08-10 | 2022-05-18 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano |
| KR102134954B1 (ko) | 2018-01-08 | 2020-07-16 | 충북대학교 산학협력단 | CEACAM6 발현 억제를 위한 siRNA 및 이를 포함하는 선암 치료제 |
| CA3091181A1 (en) * | 2018-02-13 | 2019-08-22 | Precision Biologics, Inc. | Methods and compositions for targeting treg cells |
| US11814434B2 (en) * | 2018-03-13 | 2023-11-14 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| JP7403479B2 (ja) * | 2018-06-03 | 2023-12-22 | ランカプ バイオ ベータ リミテッド | Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019379261B2 (en) * | 2018-11-14 | 2026-03-05 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-L1 antibodies for the treatment of cancer |
| EP3897844B1 (en) * | 2018-12-19 | 2023-11-15 | Deutsches Krebsforschungszentrum | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| TW202100560A (zh) * | 2019-06-04 | 2021-01-01 | 大陸商上海吉倍生物技術有限公司 | 一種抗ceacam5 的單殖株抗體及其製備方法和用途 |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| US20230115540A1 (en) * | 2020-03-06 | 2023-04-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor targeted fluorescence guidance for intraoperative margin assessment |
| CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN116621980B (zh) * | 2020-10-21 | 2025-10-28 | 北京纽安博生物技术有限公司 | 抗ceacam6单域抗体及其融合蛋白和应用 |
| WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
| KR20240028325A (ko) * | 2020-12-11 | 2024-03-05 | 매터리어 테라퓨틱스 인크. | 체크포인트 억제제와 조합하여 보센탄을 사용하는 암 치료 |
| WO2022133089A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
| CN112521509B (zh) * | 2020-12-23 | 2022-07-08 | 姚雪英 | 一种抗ceacam5人源化抗体、其缀合物及其用途 |
| US20240368280A1 (en) | 2021-09-02 | 2024-11-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
| AU2023237620A1 (en) | 2022-03-23 | 2024-08-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
| CN116196415B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 用于增敏pd-1抗体的混合制剂及其使用方法 |
| WO2024243217A1 (en) * | 2023-05-25 | 2024-11-28 | BioLegend, Inc. | Ceacam6 binding antibodies and antigen-binding fragments thereof |
| WO2025237329A1 (en) * | 2024-05-15 | 2025-11-20 | Nona Biosciences (Suzhou) Co., Ltd. | Ceacam6-binding protein |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| US8404812B2 (en) * | 2010-02-26 | 2013-03-26 | Dinona Inc. | Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| WO2012040824A1 (en) * | 2010-10-01 | 2012-04-05 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| US10131712B2 (en) | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| JP6623353B2 (ja) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | 抗ｐｄ−１抗体並びにその治療及び診断のための使用 |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| CA2980390A1 (en) | 2015-03-23 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
| CN107847589B (zh) | 2015-04-01 | 2022-03-29 | 安奈普泰斯生物有限公司 | 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体 |
| PL3443009T3 (pl) | 2016-04-12 | 2022-01-31 | Symphogen A/S | Przeciwciała i kompozycje anty-tim-3 |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| US11220543B2 (en) | 2016-11-14 | 2022-01-11 | Dinona | Antibody binding specifically to CD66c and use thereof |
| SG10201913083SA (en) | 2017-01-09 | 2020-03-30 | Tesaro Inc | Methods of treating cancer with anti-tim-3 antibodies |
-
2016
- 2016-03-21 CA CA2980390A patent/CA2980390A1/en active Pending
- 2016-03-21 SG SG11201707800QA patent/SG11201707800QA/en unknown
- 2016-03-21 TW TW105108621A patent/TWI719969B/zh active
- 2016-03-21 PT PT167137843T patent/PT3274370T/pt unknown
- 2016-03-21 DK DK16713784.3T patent/DK3274370T3/da active
- 2016-03-21 HU HUE16713784A patent/HUE048111T2/hu unknown
- 2016-03-21 BR BR112017020373-1A patent/BR112017020373A2/pt not_active IP Right Cessation
- 2016-03-21 JP JP2017549507A patent/JP6815329B2/ja active Active
- 2016-03-21 LT LTEP16713784.3T patent/LT3274370T/lt unknown
- 2016-03-21 ES ES16713784T patent/ES2768784T3/es active Active
- 2016-03-21 RU RU2017137010A patent/RU2739163C2/ru active
- 2016-03-21 EP EP16713784.3A patent/EP3274370B1/en active Active
- 2016-03-21 PE PE2017001579A patent/PE20171790A1/es unknown
- 2016-03-21 EP EP19202632.6A patent/EP3628688A1/en active Pending
- 2016-03-21 AU AU2016236270A patent/AU2016236270B2/en active Active
- 2016-03-21 SI SI201630585T patent/SI3274370T1/sl unknown
- 2016-03-21 WO PCT/EP2016/056104 patent/WO2016150899A2/en not_active Ceased
- 2016-03-21 MX MX2017012278A patent/MX376973B/es active IP Right Grant
- 2016-03-21 PL PL16713784T patent/PL3274370T3/pl unknown
- 2016-03-21 RS RS20200132A patent/RS59878B1/sr unknown
- 2016-03-21 HR HRP20192280TT patent/HRP20192280T1/hr unknown
- 2016-03-21 US US15/561,013 patent/US10584167B2/en active Active
- 2016-03-21 CN CN201680024895.XA patent/CN107743495B/zh active Active
- 2016-03-21 KR KR1020177029946A patent/KR102749339B1/ko active Active
- 2016-03-22 AR ARP160100772A patent/AR104047A1/es not_active Application Discontinuation
-
2017
- 2017-09-17 IL IL254534A patent/IL254534B/en unknown
- 2017-10-20 ZA ZA2017/07138A patent/ZA201707138B/en unknown
-
2020
- 2020-01-29 US US16/776,326 patent/US11773164B2/en active Active
- 2020-01-29 US US16/776,329 patent/US11866495B2/en active Active
- 2020-02-13 CY CY20201100133T patent/CY1122627T1/el unknown
- 2020-12-22 JP JP2020212437A patent/JP7185379B2/ja active Active